arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Alaunos Therapeutics, Inc.

TCRT
$1.82 ▲ +0.02 (+1.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
74 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Alaunos Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.4M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -115.3% ↘
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book 6.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-952.00K
↑ +9.4% —
FCF / Share Free cash flow per share
$-0.12
↑ +76.7% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
3
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 23 years · 74 quarters